IBYME   02675
INSTITUTO DE BIOLOGIA Y MEDICINA EXPERIMENTAL
Unidad Ejecutora - UE
artículos
Título:
17Beta-Estradiol Enhances Leptin Expression in Human Placental Cells Through Genomic and Nongenomic Actions
Autor/es:
GAMBINO YP; MAYMÓ J; PÉREZ-PÉREZ A; DUEÑAS JL; SANCHEZ-MARGALET V; CALVO JC; VARONE C
Revista:
BIOLOGY OF REPRODUCTION
Editorial:
SOC STUDY REPRODUCTION
Referencias:
Año: 2010
ISSN:
0006-3363
Resumen:
The process of embryo implantation and trophoblast invasion is considered the most limiting factor in the establishment of pregnancy.  Leptin  was  originally  described  as  an  adipocyte-derived signaling molecule for the central control of metabolism. However, it has been suggested that leptin is involved in other functions during pregnancy, particularly in the placenta, where it was found to be expressed. In the present work, we have  found  a  stimulatory  effect  of  17beta-estradiol  (E2) on endogenous leptin expression, as analyzed by Western blot, in both the BeWo choriocarcinoma cell line and normal placental explants.  This  effect  was  time  and  dose  dependent.  Maximal effect  was  achieved  at  10  nM  in  BeWo  cells  and  1  nM  in placental explants. The E2 effects involved the estrogen receptor, as  the  antagonist  ICI  182 780  inhibited  E2-induced  leptin expression. Moreover, E2 treatment enhanced leptin promoter activity up to 4-fold, as evaluated by transient transfection with a plasmid construction containing the leptin promoter region and the reporter gene luciferase. This effect was dose dependent. Deletion analysis demonstrated that a minimal promoter region between [1] 1951 and [1] 1847 bp is both necessary and sufficient to achieve E2 effects. Estradiol action involved estrogen receptor a, previously known as estrogen receptor alpha, as cotransfection with  a  vector  encoding  estrogen  receptor  a  potentiated  the effects of E2 on leptin expression. Moreover, E2 action probably involves  membrane  receptors  too,  as  treatment  with  an estradiol-bovine  serum  albumin  complex  partially  enhanced leptin  expression.  The  effects  of  E2 could  be  blocked  by pharmacologic inhibition of MAPK and the phosphoinositide-3-kinase  (PI3K)  pathways  with  50  lM  PD98059  and  0.1  lM Wortmannin,  respectively.  Moreover,  cotransfection  of  dominant negative mutants of MAP2K or MAPK blocked E2 induction of leptin promoter. On the other hand, E2 treatment promoted MAPK1/MAPK3 and AKT phosphorylation in placental cells. In conclusion,  we  provide  evidence  suggesting  that  E2 induces leptin  expression  in  trophoblastic  cells,  probably  through genomic and nongenomic actions via crosstalk between estrogen receptor a and MAPK and PI3K signal transduction pathways.